
FDA Releases Final Biosimilar Guidance
FDA releases long-awaited guidance documents regarding the assessment of biosimilarity.
FDA released final guidance documents on biosimilar products on Apr. 28, 2015. The three documents are:
The documents address comments from various industry perspectives and, according to FDA, “are intended to provide predictability and to make clear the scientific and regulatory considerations for sponsors initiating biosimilar development programs.”
Source: FDA
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.